Shots:
- The CHMP has recommended elinzanetant for treating mod. to sev. vasomotor symptoms linked with menopause or caused by AET related to breast cancer based on P-III (OASIS-1, 2, 3 & 4) trials
- OASIS-1 & 2 showed reduced mod. to sev. menopausal VMS vs. PBO at wks. 4 & 12, with >80% pts (incl. those who switched from PBO) achieved ≥50% VMS reduction by wk. 26, while meeting all 3 key 2EPs of reduced VMS frequency, improved sleep & QoL; published in The JAMA
- OASIS-3 also depicted reduced mod. to sev. VMS vs. PBO over 12wks. with benefits maintained over 52wks. (published in The JAMA Internal Medicine), while OASIS-4 showed similar VMS, sleep, & QoL improvements in women on HR+ breast cancer endocrine therapy (published in The NEJM)
Ref: Bayer | Image: Bayer | Press Release
Related News:- Bayer Reports the US FDA’s NDA Acceptance of Gadoquatrane for Contrast-Enhanced MRI
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
